Wedbush initiated coverage on Avalo Therapeutics with a new price target
$AVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $15.00 | Buy | H.C. Wainwright |
| 3/25/2025 | $36.00 | Buy | Stifel |
| 3/25/2025 | $23.00 | Buy | Jefferies |
| 2/28/2025 | $48.00 | Overweight | Piper Sandler |
| 2/21/2025 | $18.00 | Outperform | Wedbush |
| 12/19/2024 | $40.00 | Buy | BTIG Research |
| 10/24/2024 | Neutral | H.C. Wainwright | |
| 4/16/2024 | $35.00 | Perform → Outperform | Oppenheimer |
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
H.C. Wainwright resumed coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $15.00
Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00
Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00